Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) Pfeffer MA et al. - With several-fold more patient-years and a placebo arm, TREAT will provide a robust estimate of the safety and efficacy of darbepoetin alfa and generate prospective data regarding the risks of major cardiovascular and renal events in a contemporarily managed cohort of patients with type 2 diabetes, CKD, and anemia. [more...]
